UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~December~~January 2110, ~~2022~~2023

Lucira Health, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-39976	27-2491037
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1412 62nd Street Emeryville, California		94608
1315 63rd St Emeryville, California	94608
(Address of Principal Executive Offices)	(Zip Code)	~~(Zip Code)~~

Registrant’s Telephone Number, Including Area Code: (510) 350-8071

1412 62nd Street, Emeryville, California 94608

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	LHDX	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 15.02 ~~Termination~~Departure of aDirectors ~~Material~~or ~~Definitive~~Certain ~~Agreement.~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

OnAppointment December 21, 2022, Lucira Health, Inc. (the “Company”) repaid in its entirety and voluntarily terminated its loan and security agreement, dated February 4, 2022 (as amended, the “Loan Agreement”), by and among the Company, Hercules Capital, Inc. (“Hercules”), in its capacity as administrative agent and collateral agent (in such capacity, the “Agent”), and Hercules and Silicon Valley Bank as lenders, which had provided for term loans in an aggregate principal amount of upChief toFinancial ~~$80.0 million~~Officer ~~available in four tranches (the “Term Loans”).~~

~~The~~Effective ~~Loan Agreement was scheduled to mature on February~~January 110, ~~2026; however~~2023, the ~~Company~~board ~~elected~~of todirectors ~~repay~~of ~~all~~Lucira ~~amounts~~Health, ~~outstanding~~Inc. ~~under~~ (the ~~Loan~~“Company”) ~~Agreement~~appointed ~~using~~Richard ~~cash~~Narido onto ~~hand.~~serve ~~The~~as ~~Company~~Chief ~~paid~~Financial anOfficer. ~~end of term charge of $1~~Mr.~~075~~ ~~million~~Narido inhas ~~connection~~been ~~with~~serving ~~the~~as ~~termination of~~ the ~~Loan~~Company’s ~~Agreement.~~interim AsChief ~~collateral~~Financial ~~for~~Officer ~~the~~as ~~obligations,~~well ~~the~~as ~~Company~~principal ~~granted~~financial toofficer ~~the~~and ~~Agent~~principal aaccounting ~~senior~~officer ~~security~~since ~~interest in all of Company’s right~~November 15, ~~title~~2022, and ~~interest~~he ~~in,~~will tocontinue ~~and~~in ~~under~~the ~~substantially~~roles ~~all~~ of ~~Company’s~~principal ~~personal~~financial ~~property~~officer and ~~other~~principal ~~assets,~~accounting ~~excluding~~officer. ~~certain~~The ~~intellectual~~disclosures ~~property~~required ~~assets,~~by ~~and,~~Form ~~upon~~8-K ~~the~~Item ~~termination~~5.02(c)(2) ofand ~~the~~(3) are ~~Loan~~included ~~Agreement,~~in ~~all~~Item ~~security~~5 ~~interests~~of ~~granted~~the toCompany’s ~~the~~Quarterly ~~secured~~Report ~~parties~~on ~~thereunder~~Form ~~were~~10-Q ~~terminated~~filed ~~and~~on ~~released~~November 14, 2022.

~~The~~Mr. Narido ~~Term~~will ~~Loans~~be ~~bore~~eligible ~~interest~~to atparticipate ain ~~per~~the ~~annum~~Company’s ~~rate~~Officer ~~equal~~Severance toBenefit ~~the~~Plan, ~~greater~~a copy of ~~(i)~~which ~~(a)~~is ~~5.50%~~incorporated ~~plus~~by ~~(b) the~~reference ~~prime rate (~~as ~~reported~~Exhibit in10.5 to the ~~Wall~~Company’s ~~Street~~Annual ~~Journal)~~Report ~~and~~on ~~(ii)~~Form ~~8.75%.~~10-K ~~The~~for ~~Loan~~the ~~Agreement~~year ~~contained~~ended ~~customary events of default~~December 31, ~~representations and warranties and covenants~~2021, ~~including~~filed ~~financial~~with ~~covenants requiring~~ the ~~Company~~SEC toon ~~maintain~~March 31, ~~certain~~2022. ~~minimum~~Mr. Narido ~~cash~~will ~~and~~enter ~~revenue~~into ~~levels~~the ~~upon~~Company’s ~~the~~standard ~~occurrence~~form of ~~specified~~Indemnity ~~events~~Agreement asfor ~~more~~directors ~~fully~~and ~~set~~executive ~~forth~~officers inof the ~~Loan Agreement~~Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Lucira Health, Inc.

Date: December 28, 2022

/s/ Richard Narido

Date: January 13, 2023

/s/ Richard Narido

Richard Narido Interim Chief Financial Officer

Richard Narido Chief Financial Officer

Filing Compare · Lucira Health, Inc.